Literature DB >> 33804464

Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis.

Valentin Mocanu1, Sabitha Rajaruban2, Jerry Dang1, Janice Y Kung3, Edward C Deehan2, Karen L Madsen2.   

Abstract

The response of patients with inflammatory bowel disease (IBD) to fecal microbial transplantation (FMT) has been inconsistent possibly due to variable engraftment of donor microbiota. This failure to engraft has resulted in the use of several different strategies to attempt optimization of the recipient microbiota following FMT. The purpose of our study was to evaluate the effects of two distinct microbial strategies-antibiotic pre-treatment and repeated FMT dosing-on IBD outcomes. A systematic literature review was designed and implemented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A medical librarian conducted comprehensive searches in MEDLINE, Embase, Scopus, Web of Science Core Collection, and Cochrane Library on 25 November 2019 and updated on 29 January 2021. Primary outcomes of interest included comparing relapse and remission rates in patients with IBD for a single FMT dose, repeated FMT dosages, and antibiotic pre-treatment groups. Twenty-eight articles (six randomized trials, 20 cohort trials, two case series) containing 976 patients were identified. Meta-analysis revealed that both repeated FMT and antibiotic pre-treatment strategies demonstrated improvements in pooled response and remission rates. These clinical improvements were associated with increases in fecal microbiota richness and α-diversity, as well as the enrichment of several short-chain fatty acid (SCFA)-producing anaerobes including Bifidobacterium, Roseburia, Lachnospiraceae, Prevotella, Ruminococcus, and Clostridium related species.

Entities:  

Keywords:  antibiotic treatment; fecal microbial transplantation; inflammatory bowel disease

Year:  2021        PMID: 33804464      PMCID: PMC7957789          DOI: 10.3390/jcm10050959

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  61 in total

1.  Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn's Disease.

Authors:  Zhenyu Yang; Chibin Bu; Wei Yuan; Zhaohua Shen; Yongsheng Quan; Shuai Wu; Changxin Zhu; Xiaoyan Wang
Journal:  Dig Dis Sci       Date:  2019-07-31       Impact factor: 3.199

2.  Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis.

Authors:  Dai Ishikawa; Takashi Sasaki; Taro Osada; Kyoko Kuwahara-Arai; Keiichi Haga; Tomoyoshi Shibuya; Keiichi Hiramatsu; Sumio Watanabe
Journal:  Inflamm Bowel Dis       Date:  2017-01       Impact factor: 5.325

3.  Role of Faecal Microbiota Transplantation for Maintenance of Remission in Patients With Ulcerative Colitis: A Pilot Study.

Authors:  Ajit Sood; Ramit Mahajan; Arshdeep Singh; Vandana Midha; Varun Mehta; Vikram Narang; Tarundeep Singh; Anmol Singh Pannu
Journal:  J Crohns Colitis       Date:  2019-09-27       Impact factor: 9.071

Review 4.  Linking Microbiota to Human Diseases: A Systems Biology Perspective.

Authors:  Hao Wu; Valentina Tremaroli; Fredrik Bäckhed
Journal:  Trends Endocrinol Metab       Date:  2015-11-07       Impact factor: 12.015

5.  Fecal Microbiota Transplantation: An Update on Clinical Practice.

Authors:  Kyeong Ok Kim; Michael Gluck
Journal:  Clin Endosc       Date:  2019-03-26

6.  Low Level Engraftment and Improvement following a Single Colonoscopic Administration of Fecal Microbiota to Patients with Ulcerative Colitis.

Authors:  Christopher J Damman; Mitchell J Brittnacher; Maria Westerhoff; Hillary S Hayden; Matthew Radey; Kyle R Hager; Sara R Marquis; Samuel I Miller; Timothy L Zisman
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

Review 7.  The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation.

Authors:  Amy Langdon; Nathan Crook; Gautam Dantas
Journal:  Genome Med       Date:  2016-04-13       Impact factor: 11.117

8.  Short-Term Surveillance of Cytokines and C-Reactive Protein Cannot Predict Efficacy of Fecal Microbiota Transplantation for Ulcerative Colitis.

Authors:  Ting Zhang; Bota Cui; Pan Li; Zhi He; Chuyan Long; Lu Wei; Zhaoyuan Peng; Guozhong Ji; Faming Zhang
Journal:  PLoS One       Date:  2016-06-27       Impact factor: 3.240

9.  The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.

Authors:  P Kump; P Wurm; H P Gröchenig; H Wenzl; W Petritsch; B Halwachs; M Wagner; V Stadlbauer; A Eherer; K M Hoffmann; A Deutschmann; G Reicht; L Reiter; P Slawitsch; G Gorkiewicz; C Högenauer
Journal:  Aliment Pharmacol Ther       Date:  2017-10-20       Impact factor: 8.171

10.  Recurrence of moderate to severe ulcerative colitis after fecal microbiota transplantation treatment and the efficacy of re-FMT: a case series.

Authors:  Xiao-Fei Dang; Zhao Yin; Lin Sun; Wei-Hua Yang
Journal:  BMC Gastroenterol       Date:  2020-11-26       Impact factor: 3.067

View more
  4 in total

1.  Alteration of Gut Microbiota Relates to Metabolic Disorders in Primary Aldosteronism Patients.

Authors:  Yu Liu; Qingyao Jiang; Zhihong Liu; Sikui Shen; Jianzhong Ai; Yuchun Zhu; Liang Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-17       Impact factor: 5.555

2.  Strain-resolved analysis in a randomized trial of antibiotic pretreatment and maintenance dose delivery mode with fecal microbiota transplant for ulcerative colitis.

Authors:  Byron J Smith; Yvette Piceno; Martin Zydek; Bing Zhang; Lara Aboud Syriani; Jonathan P Terdiman; Zain Kassam; Averil Ma; Susan V Lynch; Katherine S Pollard; Najwa El-Nachef
Journal:  Sci Rep       Date:  2022-04-01       Impact factor: 4.379

3.  Study on the Antipyretic and Anti-inflammatory Mechanism of Shuanghuanglian Oral Liquid Based on Gut Microbiota-Host Metabolism.

Authors:  Yan Gao; Lu Liu; Chen Li; Yu-Ting Liang; Jing Lv; Long-Fei Yang; Bo-Nian Zhao
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

4.  A Randomized Placebo-Controlled Trial of Combination Therapy With Post-triple-antibiotic-therapy Fecal Microbiota Transplantation and Alginate for Ulcerative Colitis: Protocol.

Authors:  Dai Ishikawa; Xiaochen Zhang; Kei Nomura; Natsumi Seki; Mayuko Haraikawa; Keiichi Haga; Tomoyoshi Shibuya; Yun-Gi Kim; Akihito Nagahara
Journal:  Front Med (Lausanne)       Date:  2022-02-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.